Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06705062 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Active, Not Recruiting to Recruiting
    • Start date: Nov 1, 2024 to Jan 1, 2025
    • Site details revised
    v3
  2. Primary endpoint revisedv2 Show 4 more changesShow less
    • Secondary endpoints revised (8)
    • Study description expanded, about 7 words
    • Collaborator revised
    • Study title expanded, about 1 word
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-center randomized study to compare the reduced-dose of post-transplantation cyclophosphamide (PTCY) at 35mg.kg to standard dose at 50mg/kg combined with tacrolimus and post-engraftment low dose anti-thymoglobin (ATG) as graft versus host disease (GVHD) prophylaxis in patients undergoing allogeneic stem cell transplantation from alternative donor.
Trial Details
NCT Number NCT06705062
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Collaborators: Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Conditions
(from sponsor)		 Allogeneic Hematopoietic Cell Transplant, Graft Versus Host Disease
Related terms Graft vs Host Disease
Enrollment 316 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov